Your browser doesn't support javascript.
loading
HER2 Status in Advanced or Metastatic Gastric, Esophageal, or Gastroesophageal Adenocarcinoma for Entry to the TRIO-013/LOGiC Trial of Lapatinib.
Press, Michael F; Ellis, Catherine E; Gagnon, Robert C; Grob, Tobias J; Buyse, Marc; Villalobos, Ivonne; Liang, Zhiyong; Wu, Shafei; Bang, Yung-Jue; Qin, Shu-Kui; Chung, Hyun Cheol; Xu, Jianming; Park, Joon Oh; Jeziorski, Krzysztof; Afenjar, Karen; Ma, Yanling; Estrada, Monica C; Robinson, Douglas M; Scherer, Stefan J; Sauter, Guido; Hecht, J Randolph; Slamon, Dennis J.
Afiliación
  • Press MF; Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, California. press@usc.edu.
  • Ellis CE; GlaxoSmithKline, Philadelphia, Pennsylvania.
  • Gagnon RC; Bristol-Myers Squibb Company, Princeton, New Jersey.
  • Grob TJ; Institute of Pathology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
  • Buyse M; International Drug Development Institute, Leuven, Belgium.
  • Villalobos I; Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, California.
  • Liang Z; Department of Pathology, Peking Union Medical College Hospital, Chinese Academy of Medical Science, Beijing, P.R. China.
  • Wu S; Department of Pathology, Peking Union Medical College Hospital, Chinese Academy of Medical Science, Beijing, P.R. China.
  • Bang YJ; Seoul National University College of Medicine, Seoul, Republic of Korea.
  • Qin SK; PLA Cancer Center, Nanjing Bayi Hospital, Jiangsu, China.
  • Chung HC; Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Korea.
  • Xu J; The Affiliated Hospital Cancer Center, Academy of Military Medical Sciences, Beijing, China.
  • Park JO; Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea.
  • Jeziorski K; Maria Sklodowska-Curie Memorial Cancer Centre and Institute of Oncology, Warsaw, Poland.
  • Afenjar K; Translational Research in Oncology, Paris, France.
  • Ma Y; Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, California.
  • Estrada MC; Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, California.
  • Robinson DM; Novartis Pharmaceutical Corporation, East Hanover, New Jersey.
  • Scherer SJ; Novartis Pharmaceutical Corporation, East Hanover, New Jersey.
  • Sauter G; Institute of Pathology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
  • Hecht JR; Division of Hematology/Oncology, David Geffen School of Medicine at UCLA, Santa Monica, California.
  • Slamon DJ; Division of Hematology/Oncology, David Geffen School of Medicine at UCLA, Santa Monica, California.
Mol Cancer Ther ; 16(1): 228-238, 2017 01.
Article en En | MEDLINE | ID: mdl-27811012
Asunto(s)
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Quinazolinas / Neoplasias Gástricas / Neoplasias Esofágicas / Adenocarcinoma / Receptor ErbB-2 / Inhibidores de Proteínas Quinasas Tipo de estudio: Clinical_trials / Risk_factors_studies Límite: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Revista: Mol Cancer Ther Asunto de la revista: ANTINEOPLASICOS Año: 2017 Tipo del documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Quinazolinas / Neoplasias Gástricas / Neoplasias Esofágicas / Adenocarcinoma / Receptor ErbB-2 / Inhibidores de Proteínas Quinasas Tipo de estudio: Clinical_trials / Risk_factors_studies Límite: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Revista: Mol Cancer Ther Asunto de la revista: ANTINEOPLASICOS Año: 2017 Tipo del documento: Article